Tianliang Zhang

PhD-trained scientist with 7+ years of experience in translational oncology, tumor biology, immunology, and virology, with strong expertise in in vivo pharmacology and immune-based cancer research. Proven ability to design and execute integrated in vitro and in vivo studies to investigate tumor biology, immune responses, and therapeutic mechanisms. Hands-on experience in murine tumor models, xenografts, and preclinical efficacy studies, combined with strong capabilities in molecular and cellular biology, including CRISPR/Cas9 gene editing, molecular cloning, qPCR, Western blotting, and RNA-seq-guided target exploration. Experienced in T cell biology and viral vector systems, including T cell isolation, activation, expansion, and culture, as well as lentiviral vector packaging, titration, and transduction workflows. Skilled in multi-color flow cytometry, cytotoxicity assays, ELISA, and immune phenotyping. Strong track record of leading independent research projects, troubleshooting complex experimental systems, and translating mechanistic findings into actionable preclinical insights. Co-author of publications in journals including The Journal of Clinical Investigation and Nature Metabolism. Core areas of expertise include: Translational oncology and tumor biology In vivo pharmacology and murine tumor models CRISPR/Cas9 and functional genomics Flow cytometry, qPCR, Western blotting, and histology Mechanism-of-action studies and pathway biology Preclinical study design and cross-functional scientific collaboration I am currently exploring industry opportunities in immuno-oncology, cell therapy, in vivo pharmacology, and translational research.